FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3182921423> ?p ?o ?g. }

• W3182921423 abstract "Backgroud: Tumor mutation burden (TMB) remains a promising but ambiguous biomarker for the efficacy of immune checkpoint inhibitors (ICIs)-based regimens. We conducted multifaceted systematic review and meta-analysis, and public cohort validation, to provide pooled evidence of the prediction value of TMB for ICIs in advanced non-small cell lung cancer (NSCLC).Methods: Mirror-based meta-analysis balancing the confounding factors was applied in Part1, and Bayesian network meta-analysis was conducted in Part2. PubMed, Embase, and Cochrane Central were searched and abstracts from conference were reviewed. All randomized controlled trials (RCTs) that investigated the predictive value of TMB in advanced NSCLC patients receiving ICIs were included. Baseline characteristics, hazard ratios (HRs) with 95% confidence intervals (95% CIs) for progression-free survival (PFS) and overall survival (OS) stratified by TMB status were extracted. Furthermore, public cohorts of advanced NSCLC treated with ICIs with genomic sequencing were analyzed in Part 3.Results: 10 RCTs covering 4443 patients and 5 public cohorts with 573 patients as validation were included. 9 RCTs were included inPart1a. TMB-high subgroup exhibited significantly superior PFS than TMB-low subgroup (HR 0.56, 95% CI 0.47-0.67) in NSCLC treated with ICIs compared with chemotherapy, and such superiority was consistent in the preplanned subgroup analysis based on the line of therapy, regimen modality, test method of TMB and PD-L1 expression. 7 RCTs were included in Part1b. No significant difference of PFS or OS was observed between anti-PD-L1 and anti-PD-1 according to TMB status. 7 RCTs were included in Part2. Among all first-line regimens in TMB-high group, platinum-based doublet chemotherapy combined with anti-PD-1 was most likely to rank first for PFS (probability of ranking best 48.29%, surface under the cumulative ranking curve 0.83), anti-PD-L1 plus anti-cytotoxic T-lymphocyte A antigen-4 (CTLA-4) provided the most favorable OS (63.89%, 0.86), and platinum-based chemotherapy ranked worst for PFS (0.03%, 0.11) and OS (0.02%, 0.09). In Part3, TMB was validated to be an independent predictor, which could further distinguish beneficiaries of ICIs in those with PD-L1 expression less than 50%.Conclusions: TMB could be used to identify beneficiaries of ICIs contained therapies and played a crucial role in determining the optimal first-line treatment among various available strategy for advanced NSCLC patients.Citation Format: Jie Zhao, Yiting Dong, Hua Bai, Jianchun Duan, Guoqiang Wang, Jiachen Xu, Zhijie Wang, Jie Wang. The effect of tumor mutation burden on immune checkpoint inhibitors in non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1614." @default.
• W3182921423 created "2021-07-19" @default.
• W3182921423 creator A5018396032 @default.
• W3182921423 creator A5028986154 @default.
• W3182921423 creator A5038578997 @default.
• W3182921423 creator A5045870875 @default.
• W3182921423 creator A5047497776 @default.
• W3182921423 creator A5063835503 @default.
• W3182921423 creator A5075877965 @default.
• W3182921423 creator A5090029664 @default.
• W3182921423 date "2021-07-01" @default.
• W3182921423 modified "2023-10-15" @default.
• W3182921423 title "Abstract 1614: The effect of tumor mutation burden on immune checkpoint inhibitors in non-small cell lung cancer" @default.
• W3182921423 doi "https://doi.org/10.1158/1538-7445.am2021-1614" @default.
• W3182921423 hasPublicationYear "2021" @default.
• W3182921423 type Work @default.
• W3182921423 sameAs 3182921423 @default.
• W3182921423 citedByCount "0" @default.
• W3182921423 crossrefType "proceedings-article" @default.
• W3182921423 hasAuthorship W3182921423A5018396032 @default.
• W3182921423 hasAuthorship W3182921423A5028986154 @default.
• W3182921423 hasAuthorship W3182921423A5038578997 @default.
• W3182921423 hasAuthorship W3182921423A5045870875 @default.
• W3182921423 hasAuthorship W3182921423A5047497776 @default.
• W3182921423 hasAuthorship W3182921423A5063835503 @default.
• W3182921423 hasAuthorship W3182921423A5075877965 @default.
• W3182921423 hasAuthorship W3182921423A5090029664 @default.
• W3182921423 hasConcept C126322002 @default.
• W3182921423 hasConcept C143998085 @default.
• W3182921423 hasConcept C168563851 @default.
• W3182921423 hasConcept C187960798 @default.
• W3182921423 hasConcept C207103383 @default.
• W3182921423 hasConcept C2776256026 @default.
• W3182921423 hasConcept C2781413609 @default.
• W3182921423 hasConcept C44249647 @default.
• W3182921423 hasConcept C71924100 @default.
• W3182921423 hasConcept C72563966 @default.
• W3182921423 hasConcept C95190672 @default.
• W3182921423 hasConceptScore W3182921423C126322002 @default.
• W3182921423 hasConceptScore W3182921423C143998085 @default.
• W3182921423 hasConceptScore W3182921423C168563851 @default.
• W3182921423 hasConceptScore W3182921423C187960798 @default.
• W3182921423 hasConceptScore W3182921423C207103383 @default.
• W3182921423 hasConceptScore W3182921423C2776256026 @default.
• W3182921423 hasConceptScore W3182921423C2781413609 @default.
• W3182921423 hasConceptScore W3182921423C44249647 @default.
• W3182921423 hasConceptScore W3182921423C71924100 @default.
• W3182921423 hasConceptScore W3182921423C72563966 @default.
• W3182921423 hasConceptScore W3182921423C95190672 @default.
• W3182921423 hasLocation W31829214231 @default.
• W3182921423 hasOpenAccess W3182921423 @default.
• W3182921423 hasPrimaryLocation W31829214231 @default.
• W3182921423 hasRelatedWork W2130616545 @default.
• W3182921423 hasRelatedWork W2401656611 @default.
• W3182921423 hasRelatedWork W2734975679 @default.
• W3182921423 hasRelatedWork W2746182731 @default.
• W3182921423 hasRelatedWork W2889691785 @default.
• W3182921423 hasRelatedWork W2893418727 @default.
• W3182921423 hasRelatedWork W2938061249 @default.
• W3182921423 hasRelatedWork W3185003217 @default.
• W3182921423 hasRelatedWork W4206071870 @default.
• W3182921423 hasRelatedWork W4291824836 @default.
• W3182921423 isParatext "false" @default.
• W3182921423 isRetracted "false" @default.
• W3182921423 magId "3182921423" @default.
• W3182921423 workType "article" @default.